Dubuque Bank & Trust Co. lifted its stake in shares of AbbVie Inc (NYSE:ABBV) by 2.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 84,943 shares of the company’s stock after purchasing an additional 2,141 shares during the quarter. AbbVie accounts for 1.2% of Dubuque Bank & Trust Co.’s holdings, making the stock its 21st biggest holding. Dubuque Bank & Trust Co.’s holdings in AbbVie were worth $8,034,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Signature Estate & Investment Advisors LLC acquired a new stake in AbbVie in the third quarter valued at about $112,000. First Mercantile Trust Co. acquired a new stake in AbbVie in the second quarter valued at about $150,000. MUFG Securities EMEA plc acquired a new stake in AbbVie in the second quarter valued at about $157,000. Kiley Juergens Wealth Management LLC boosted its stake in AbbVie by 69.3% in the third quarter. Kiley Juergens Wealth Management LLC now owns 1,761 shares of the company’s stock valued at $166,000 after buying an additional 721 shares in the last quarter. Finally, S. R. Schill & Associates acquired a new stake in AbbVie in the second quarter valued at about $200,000. 69.85% of the stock is currently owned by institutional investors.
In other news, insider Laura J. Schumacher sold 94,140 shares of the firm’s stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $93.58, for a total transaction of $8,809,621.20. Following the completion of the transaction, the insider now directly owns 192,398 shares in the company, valued at $18,004,604.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Henry O. Gosebruch sold 42,450 shares of the firm’s stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $90.10, for a total value of $3,824,745.00. Following the transaction, the executive vice president now owns 30,350 shares of the company’s stock, valued at $2,734,535. The disclosure for this sale can be found here. Company insiders own 0.07% of the company’s stock.
Shares of ABBV stock opened at $86.96 on Friday. AbbVie Inc has a 12 month low of $77.50 and a 12 month high of $125.86. The stock has a market cap of $136.21 billion, a PE ratio of 15.53, a PEG ratio of 0.84 and a beta of 1.68. The company has a current ratio of 1.20, a quick ratio of 1.08 and a debt-to-equity ratio of 8.70.
AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, November 2nd. The company reported $2.14 EPS for the quarter, beating the Zacks’ consensus estimate of $2.01 by $0.13. AbbVie had a return on equity of 2,006.63% and a net margin of 23.50%. The firm had revenue of $8.24 billion for the quarter, compared to analyst estimates of $8.23 billion. During the same period last year, the firm posted $1.41 earnings per share. The business’s revenue for the quarter was up 17.7% on a year-over-year basis. Equities analysts predict that AbbVie Inc will post 7.93 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, February 15th. Stockholders of record on Tuesday, January 15th will be paid a dividend of $1.07 per share. This represents a $4.28 dividend on an annualized basis and a dividend yield of 4.92%. This is a positive change from AbbVie’s previous quarterly dividend of $0.96. The ex-dividend date of this dividend is Monday, January 14th. AbbVie’s dividend payout ratio (DPR) is presently 68.57%.
Several research firms recently weighed in on ABBV. Credit Suisse Group set a $85.00 price objective on AbbVie and gave the company a “hold” rating in a research note on Sunday, October 14th. Barclays reaffirmed a “hold” rating and issued a $90.00 price objective on shares of AbbVie in a research note on Sunday, November 4th. Bank of America reduced their price objective on AbbVie from $107.00 to $106.00 and set a “buy” rating on the stock in a research note on Thursday, October 4th. Zacks Investment Research raised AbbVie from a “hold” rating to a “buy” rating and set a $105.00 price objective on the stock in a research note on Monday, October 1st. Finally, SunTrust Banks reduced their price objective on AbbVie from $157.00 to $135.00 and set a “buy” rating on the stock in a research note on Monday, October 22nd. Four analysts have rated the stock with a sell rating, seven have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $103.68.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.
Further Reading: What is the LIBOR?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.